Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Breast
Descriptor: HGF/SF expression


Reference Number: 6
Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O. & Miyazaki, K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 51, 172-8. (2001).
PubMed link      E-mail link

Reference Number: 7
Jin, L. et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79, 749-60. (1997).
PubMed link      E-mail link

Reference Number: 8
Kang, J. Y. et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63, 1101-5 (2003).
PubMed link      E-mail link

Reference Number: 9
Nagy, J. et al. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 5, 15-21. (1996).
PubMed link      E-mail link

Reference Number: 10
Tuck, A. B., Park, M., Sterns, E. E., Boag, A. & Elliott, B. E. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148, 225-32 (1996).
PubMed link      E-mail link

Reference Number: 11
Yamashita, J. et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54, 1630-3 (1994).
PubMed link      E-mail link

Reference Number: 12
Yao, Y. et al. Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am J Pathol 149, 1707-17 (1996).
PubMed link      E-mail link

Reference Number: 237
Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10:202-11 (2004).
PubMed link      E-mail link

Reference Number: 308
Coskun U, Bukan N, Sancak B, Gunel N, Ozenirler S, Unal A, Yucel A. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 51, 209-13 (2004)
PubMed link      E-mail link

Reference Number: 359
Matteucci E, Locati M, Desiderio MA. Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp Cell Res.  310 176-85 (2005)
PubMed link      E-mail link

Reference Number: 360
Sheen-Chen SM, Liu YW, Eng HL, Chou FF. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 14 715-7 (2005)
PubMed link      E-mail link

Reference Number: 404
Bigelow RL, Cardelli JA. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene. 25, 1922-30 (2006)
PubMed link      E-mail link

Reference Number: 528
Pruefer FG, Unger-Saldaña K, Mohamier L, Ramírez M, Suárez J, Ramirez MT, Maldonado V, Meléndez-Zajgla J. Tumor HGF lacks prognostic significance in Mexican breast cancer patients. J Exp Clin Cancer Res. 25, 357-64 (2006)
PubMed link      E-mail link

Reference Number: 532
Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A, Sohn C. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol. 28, 36-44 (2007)
PubMed link      E-mail link

Reference Number: 544
Matteucci E, Ridolfi E, Desiderio MA. Hepatocyte growth factor differently influences Met-E-cadherin phosphorylation and downstream signaling pathway in two models of breast cells. Cell Mol Life Sci. 63, 2016-26 (2006)
PubMed link      E-mail link

Reference Number: 547
Filigheddu N, Cutrupi S, Porporato PE, Riboni F, Baldanzi G, Chianale F, Fortina E, Piantanida P, De Bortoli M, Vacca G, Graziani A, Surico N. Diacylglycerol kinase is required for HGF-induced invasiveness and anchorage-independent growth of MDA-MB-231 breast cancer cells. Anticancer Res. 27, 1489-92 (2007)
PubMed link      E-mail link

Reference Number: 555
Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 51, 54-62 (2007)
PubMed link      E-mail link

Reference Number: 610
Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 226, 178-91 (2007)
PubMed link      E-mail link

Reference Number: 613
Sam MR, Elliott BE, Mueller CR. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol Cancer. 6, 69 (2007)
PubMed link      E-mail link

Reference Number: 636
Leibowitz-Amit R, Tsarfaty G, Abargil Y, Yerushalmi GM, Horev J, Tsarfaty I. Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways. Cancer Res. 66, 8687-97 (2006)
PubMed link      E-mail link

Reference Number: 643
Xu H, Washington S, Verderame MF, Manni A. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells. Breast Cancer Res Treat. 112, 255-61 (2008)
PubMed link      E-mail link

Reference Number: 674
Takahashi K, Suzuki K. Requirement of kinesin-mediated membrane transport of WAVE2 along microtubules for lamellipodia formation promoted by hepatocyte growth factor. Exp Cell Res. 314, 2313-22 (2008)
PubMed link      E-mail link

Reference Number: 675
Yin YL, Chen HL, Kuo HM, He SP. NK3 and NK4 of HGF enhance filamin production via STAT pathway, but not NK1 and NK2 in human breast cancer cells. Acta Pharmacol Sin. 29, 728-35 (2008)
PubMed link      E-mail link

Reference Number: 676
Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V, Mukhtar H. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol. 231, 52-60 (2008)
PubMed link      E-mail link

Reference Number: 687
Wright TG, Singh VK, Li JJ, Foley JH, Miller F, Jia Z, Elliott BE. Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model. Int J Cancer. 125, 1004-15 (2009)
PubMed link      E-mail link

Reference Number: 697
Ridolfi E, Matteucci E, Maroni P, Desiderio MA. Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br J Cancer. 99, 1623-34. Epub 2008 Oct 21 (2008)
PubMed link      E-mail link

Reference Number: 839
Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer. 46, 1679-91 (2010)
PubMed link      E-mail link

Reference Number: 848
Jedeszko C, Victor BC, Podgorski I, Sloane BF. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res. 69, 9148-55 (2009)
PubMed link      E-mail link

Reference Number: 955
Tyan SW, Kuo WH, Huang CK, Pan CC, Shew JY, Chang KJ, Lee EY, Lee WH. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One. 6, (e)15313 (2011)
PubMed link      E-mail link

Reference Number: 987
Ma J, DeFrances MC, Zou C, Johnson C, Ferrell R, Zarnegar R. Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest. 119, 478-91 (2009)
PubMed link      E-mail link

Reference Number: 1005
El-Attar HA, Ragab MS, Sheta MI, Ahmed AS. Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers. Asian Pac J Cancer Prev. 11, 893-6 (2010)
PubMed link      E-mail link

Reference Number: 1066
Kucera R, Cerna M, Narsanska A, Svobodova S, Strakova M, Vrzalova J, Fuchsova R, Treskova I, Kydlicek T, Treska V, Pecen L, Topolcan O, Pazdiora P. Growth factors and breast tumors, comparison of selected growth factors with traditional tumor markers. Anticancer Res. 31, 4653-6 (2011)
PubMed link      E-mail link

Reference Number: 1154
Kim EJ, Eom SJ, Hong JE, Lee JY, Choi MS, Park JH. Benzyl isothiocyanate inhibits basal and hepatocyte growth factor-stimulated migration of breast cancer cells. Mol Cell Biochem. 359, 431-40 (2012)
PubMed link      E-mail link

Reference Number: 1199
Ahmed HH, Metwally FM, Mahdy ES, Shosha WG, Ramadan SS. Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients. Eur Rev Med Pharmacol Sci. 16, 958-65 (2012)
PubMed link      E-mail link

Reference Number: 1200
Huang FI, Chen YL, Chang CN, Yuan RH, Jeng YM. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis. 33, 1142-8 (2012)
PubMed link      E-mail link

Reference Number: 1427
Harrison SM, Knifley T, Chen M, O'Connor KL1. LPA, HGF, and EGF utilize distinct combinations of signaling pathways to promote migration and invasion of MDA-MB-231 breast carcinoma cells. BMC Cancer. 13, 501 (2013)
PubMed link      E-mail link

Reference Number: 1451
Sundaram S1, Freemerman AJ, Johnson AR, Milner JJ, McNaughton KK, Galanko JA, Bendt KM, Darr DB, Perou CM, Troester MA, Makowski L. Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Res Treat. 142, 489-503 (2013)
PubMed link      E-mail link

Reference Number: 1541
Chen P, Mo Q, Wang B, Weng D, Wu P, Chen G. Breast cancer associated fibroblasts promote MCF-7 invasion in vitro by secretion of HGF. J Huazhong Univ Sci Technolog Med Sci. 32, 92-6 (2012)
PubMed link      E-mail link

Reference Number: 1542
Casbas-Hernandez P, D'Arcy M, Roman-Perez E, Brauer HA, McNaughton K, Miller SM, Chhetri RK, Oldenburg AL, Fleming JM, Amos KD, Makowski L, Troester MA. Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res. 15, R82 (2013)
PubMed link      E-mail link

Reference Number: 1600
Lee YH, Morrison BL, Bottaro DP. Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem. 289, 20448-61 (2014)
PubMed link      E-mail link

Reference Number: 1683
Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res. 14, R104 (2012)
PubMed link      E-mail link

Reference Number: 1733
Yang H, Zhang C, Cui S Expression of hepatocyte growth factor in breast cancer and its effect on prognosis and sensitivity to chemotherapy. Mol Med Rep. 11, 1037-42 (2015)
PubMed link      E-mail link

Reference Number: 1860
Bendinelli P, Maroni P, Matteucci E, Desiderio MA. HGF and TGFß1 differently influenced Wwox regulatory function on Twist program for mesenchymal-epithelial transition in bone metastatic versus parental breast carcinoma cells. Mol Cancer. 14, 112 (2015)
PubMed link      E-mail link